Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised ...

Upstream Bio (NASDAQ:UPB) shares rallied 32% Friday following the asthma drug developer’s $255M upsized initial public ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.

Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...

Three US life-sciences companies hitting the market delivered mostly robust early trading after investors strongly supported ...

This summary provides a snapshot of current health news, including IPO pricing by biotech startups, Sanofi's potential sale of its consumer health business, HMI Medical's acquisition in Singapore, a ...

Upstream asserts that verekitug could offer advantages over Tezpire, including potentially greater potency and longer dosing intervals. The company is testing intervals of 12 and 24 weeks in its ...

Three US life-sciences companies have so far exceeded or met their goals in initial public offerings Thursday, showing ...

Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in ...

CeriBell (CBLL) shares rallied 35% Friday following the medical device maker’s $180M initial public offering. Read more here.